2021
DOI: 10.1002/cam4.4405
|View full text |Cite
|
Sign up to set email alerts
|

First‐line immune‐based combination therapies for advanced non‐small cell lung cancer: A Bayesian network meta‐analysis

Abstract: Background Immune‐based combination therapies have revolutionized the first‐line treatment for advanced non‐small cell lung cancer (NSCLC). However, for the efficacy and safety, the best treatment option is still uncertain. Methods We conducted a Bayesian network meta‐analysis of randomized controlled trials (RCTs) to evaluate first‐line immune‐based combination therapies for advanced NSCLC. Results Fourteen trials involving 8467 patients were included. For the programmed cell death‐ligand 1 (PD‐L1) expression… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
4

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 53 publications
0
2
0
Order By: Relevance
“… 74 Several such studies have been performed in lung cancer, including evaluating safety and efficacy of bevacizumab biosimilars, 75 determining optimal platinum-based chemotherapy for early-stage resected NSCLC, 76 how smoking status influences effect of targeted therapy, 77 and choice of first-line treatment for patients on the basis of PD-L1 expression. 78 , 79 , 80 …”
Section: Treatmentmentioning
confidence: 99%
“… 74 Several such studies have been performed in lung cancer, including evaluating safety and efficacy of bevacizumab biosimilars, 75 determining optimal platinum-based chemotherapy for early-stage resected NSCLC, 76 how smoking status influences effect of targeted therapy, 77 and choice of first-line treatment for patients on the basis of PD-L1 expression. 78 , 79 , 80 …”
Section: Treatmentmentioning
confidence: 99%
“…Pembrolizumab with chemotherapy combined with paclitaxel or nab-paclitaxel could be used in squamous cell carcinoma patients. Moreover, combined treatment with nivolumab, ipilimumab, and limited chemotherapy (two cycles) finds application in the treatment of advanced NSCLC [ 9 ]. Chemoimmunotharpies result in improved PFS and OS regardless of PD-L1 expression or the presence of liver or brain metastases, although the lack of PD-L1 expression or the occurrence of metastases reduces the effectiveness of therapy [ 3 ].…”
Section: Introductionmentioning
confidence: 99%